Montelukast Unimark

Montelukast, the active ingredient in Montelukast Unimark, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma, allergic rhinitis and exercise‑induced bronchoconstriction, providing symptom control in both adult and pediatric populations across the European Union.

GNH USA supplies Montelukast Unimark as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and serving hospitals, pharmacies, and clinics worldwide with reliable global logistics and regulatory support for a broad range of therapeutic needs.

Montelukast acts on the leukotriene pathway to manage chronic respiratory and allergic conditions.

Asthma: improves control of symptoms and reduces frequency of bronchospasm. Allergic rhinitis: relieves nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Abdominal pain - Nausea

Serious or Rare Side Effects: - Angioedema - Stevens‑Johnson syndrome - Eosinophilic granulomatosis with polyangiitis

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against possible infant exposure. Hepatic impairment: use with caution and monitor liver function tests. Concomitant enzyme inducers: drugs such as phenobarbital or rifampin may lower montelukast plasma levels. Age restrictions: not recommended for children under 12 months of age. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may decrease montelukast plasma concentrations, reducing therapeutic effect. - Rifampin: strong enzyme induction can lower drug exposure and compromise control of symptoms. - Strong CYP3A4 inhibitors: may increase montelukast levels and raise risk of adverse reactions.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for enhanced neuropsychiatric effects. - Warfarin: monitor INR as montelukast may affect anticoagulant metabolism. - Beta‑agonists: additive bronchodilation may increase risk of tachycardia.